301 related articles for article (PubMed ID: 17335409)
1. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
Naidu Y; Chaudhuri KR
Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
[TBL] [Abstract][Full Text] [Related]
2. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Splinter MY
Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
[TBL] [Abstract][Full Text] [Related]
3. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
Zareba G
Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
[TBL] [Abstract][Full Text] [Related]
4. Rotigotine: Parkinson's disease: a step backward.
Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
[TBL] [Abstract][Full Text] [Related]
5. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K; Lyons KE
Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
[TBL] [Abstract][Full Text] [Related]
6. Rotigotine transdermal delivery for the treatment of Parkinson's disease.
Rascol O; Perez-Lloret S
Expert Opin Pharmacother; 2009 Mar; 10(4):677-91. PubMed ID: 19239399
[TBL] [Abstract][Full Text] [Related]
7. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.
Zesiewicz TA; Martinez-Martin P
Expert Rev Neurother; 2013 Dec; 13(12):1329-42. PubMed ID: 24236902
[TBL] [Abstract][Full Text] [Related]
8. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
Sanford M; Scott LJ
CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
[TBL] [Abstract][Full Text] [Related]
9. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Perez-Lloret S; Rey MV; Ratti PL; Rascol O
Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
[TBL] [Abstract][Full Text] [Related]
10. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on rotigotine in Parkinson's disease.
Baldwin CM; Keating GM
Drugs Aging; 2008; 25(2):175-7. PubMed ID: 18257604
[TBL] [Abstract][Full Text] [Related]
12. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
[TBL] [Abstract][Full Text] [Related]
13. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
Metman LV; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian MM; Chase TN
Clin Neuropharmacol; 2001; 24(3):163-9. PubMed ID: 11391128
[TBL] [Abstract][Full Text] [Related]
14. Rotigotine transdermal system for the treatment of Parkinson's disease.
Pham DQ; Nogid A
Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
[TBL] [Abstract][Full Text] [Related]
15. Night-time use of rotigotine in advanced Parkinson's disease.
Canesi M; Mariani CB; Isaias IU; Pezzoli G
Funct Neurol; 2010; 25(4):201-4. PubMed ID: 21388580
[TBL] [Abstract][Full Text] [Related]
16. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
Baldwin CM; Keating GM
CNS Drugs; 2007; 21(12):1039-55. PubMed ID: 18020483
[TBL] [Abstract][Full Text] [Related]
17. Transdermal rotigotine (Neupro) for Parkinson's disease.
Med Lett Drugs Ther; 2007 Aug; 49(1268):69-70. PubMed ID: 17712291
[No Abstract] [Full Text] [Related]
18. Rotigotine for the treatment of Parkinson's disease.
Morgan JC; Sethi KD
Expert Rev Neurother; 2006 Sep; 6(9):1275-82. PubMed ID: 17009915
[TBL] [Abstract][Full Text] [Related]
19. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
[TBL] [Abstract][Full Text] [Related]
20. Treatment of motor and NMS of Parkinson's disease with the rotigotine transdermal system.
Lyons KE
Neurol Clin; 2013 Aug; 31(3 Suppl):vii-ix. PubMed ID: 23931955
[No Abstract] [Full Text] [Related]
[Next] [New Search]
